Abstract:RNA editing, an essential post -transcriptional reaction occurring in double -stranded RNA (dsRNA), generates informational diversity in the transcriptome and proteome. In mammals, the main type of RNA editing is the conversion of adenosine to inosine (A -to -I), processed by adenosine deaminases acting on the RNAs (ADARs) family, and interpreted as guanosine during nucleotide base -pairing. It has been reported that millions of nucleotide sites in human transcriptome undergo A -to -I editing events, catalyzed by the primarily responsible enzyme, ADAR1. In hematological malignancies including myeloid/lymphocytic leukemia and multiple myeloma, dysregulation of ADAR1 directly impacts the A -to -I editing states occurring in coding regions, noncoding regions, and immature miRNA precursors. Subsequently, aberrant A -to -I editing states result in altered molecular events, such as protein -coding sequence changes, intron retention, alternative splicing, and miRNA biogenesis inhibition. As a vital factor of the generation and stemness maintenance in leukemia stem cells (LSCs), disordered RNA editing drives the chaos of molecular regulatory network and ultimately promotes the cell proliferation, apoptosis inhibition and drug resistance. At present, novel drugs designed to target RNA editing (e.g., rebecsinib) are under development and have achieved outstanding results in animal experiments. Compared with traditional antitumor drugs, epigenetic antitumor drugs are expected to overcome the shackle of drug resistance and recurrence in hematological malignancies, and provide new treatment options for patients. This review summarized the recent advances in the regulation mechanism of ADAR1-mediated RNA editing events in hematologic malignancies, and further discussed the medical potential and clinical application of ADAR1.

The Role of RNA Editing in Cancer Development and Metabolic Disorders

RNA editing in the forefront of epitranscriptomics and human health

RNA Editing in Cancer Progression

ADAR1-Mediated RNA Editing and Its Role in Cancer

RNA editing enzymes: structure, biological functions and applications

Non-Coding RNA Editing in Cancer Pathogenesis

The effects of RNA editing in cancer tissue at different stages in carcinogenesis

The implications of APOBEC3-mediated C-to-U RNA editing for human disease

Recent Advances in Adenosine-to-Inosine RNA Editing in Cancer

ADARs, RNA editing and more in hematological malignancies

RNA Editors, Cofactors, and mRNA Targets: An Overview of the C-to-U RNA Editing Machinery and Its Implication in Human Disease

The role of dsRNA A-to-I editing catalyzed by ADAR family enzymes in the pathogeneses

Mechanisms and Implications of ADAR-mediated RNA Editing in Cancer

The role of RNA editing enzyme ADAR1 in human disease

The Regulatory Function of ADAR1-mediated RNA Editing in Hematological Malignancies

Adenosine-to-Inosine RNA Editing: A Key RNA Processing Step Rewriting Transcriptome in Normal Physiology and Diseases

Harnessing ADAR-Mediated Site-Specific RNA Editing in Immune-Related Disease: Prediction and Therapeutic Implications

The role of ADAR1 through and beyond its editing activity in cancer

Biological roles of A-to-I editing: implications in innate immunity, cell death, and cancer immunotherapy.

ADAR-mediated RNA Editing in Non-Coding RNA Sequences

RNA A-to-I editing, environmental exposure, and human diseases